

# Glenmark Pharma

Estimate change



TP change

Rating change

Bloomberg	GNP IN
Equity Shares (m)	282
M.Cap.(INRb)/(USDb)	315.9 / 3.8
52-Week Range (INR)	1125 / 588
1, 6, 12 Rel. Per (%)	1/26/65
12M Avg Val (INR M)	1005

## Financials & Valuations (INR b)

Y/E March	FY24	FY25E	FY26E
Sales	118.1	132.5	144.2
EBITDA	13.0	24.2	26.8
Adj. PAT	0.7	12.4	14.2
EBIT Margin (%)	6.1	14.5	14.9
Adj EPS (INR)	2.5	44.1	50.4
EPS Gr. (%)	-88.0	1673.6	14.4
BV/Sh. (INR)	278.1	318.6	369.0

## Ratios

Net D-E	-0.1	0.0	0.0
ROE (%)	0.8	14.8	14.7
RoCE (%)	-777.3	15.4	15.0
Payout (%)	-5.4	8.2	0.0

## Valuations

P/E (x)	452.4	25.5	22.3
EV/EBITDA (x)	23.8	13.2	11.7
Div. Yield (%)	0.3	0.3	0.3
FCF Yield (%)	16.6	-2.6	2.3
EV/Sales (x)	2.6	2.4	2.2

## Shareholding pattern (%)

As On	Mar-24	Dec-23	Mar-23
Promoter	46.6	46.7	46.7
DII	13.4	11.0	10.5
FII	21.4	23.7	22.5
Others	18.6	18.7	20.5

FII Includes depository receipts

**CMP: INR1,124**
**TP: INR1,050 (-7%)**
**Neutral**

## Operating performance above est.; FY25 outlook better

Adverse market dynamics/de-prioritization of intangibles lead to an impairment of INR23b

- Glenmark Pharma (GNP) posted lower-than-expected revenue in 4QFY24. However, it delivered better-than-expected profitability for the quarter, aided by an improved product mix and lower raw material costs. Having said this, GNP has taken a considerable impairment charge on manufacturing facilities and certain intangibles (~INR32b) during the quarter.
- We raise our earnings estimates by 17%/10% for FY25/FY26, factoring in: 1) new launches in the US market, 2) increased market share in cardiac, derma, and respiratory products in the Domestic Formulation (DF) segment, and c) a significant reduction in interest costs. We value GNP at 21x 12M forward earnings to arrive at our TP of INR1,050.
- GNP ended FY24 with an adj. PAT of INR700m, the lowest historically. However, new approvals in the US, changes in distribution model in the DF business, and financial deleverage would enable a sharp revival in earnings over FY24-26. The current valuation adequately captures the improvement in earnings over the next two years. **Reiterate Neutral**.

## Product mix and lower R&D expenses drive margins YoY

- GNP's revenue grew 2% YoY to INR30.6b (our estimate of INR32b). DF grew 13.4% YoY to INR9.4b (30% of sales). RoW sales rose 9.8% YoY to INR7.5b (25% of sales). Europe generics revenue was flat YoY at INR6.1b (20% of sales). NA revenue declined 11% YoY to INR7.6b (USD91m; 25% of sales).
- Gross margin (GM) expanded 600bp YoY to 67.5% due to lower RM costs and a change in product mix.
- EBITDA margin expanded 320bp YoY due to favorable GP margin, offset by higher employee expenses/other expenses (up 240bp/40bp as a % of sales).
- GNP had exceptional items for the quarter: Out of the exceptional gains of INR54.5b due to the 75% stake sale of Glenmark Life (GLS), there was a deduction of INR19b related to reserves of GLS, an effective gain of INR35.7b. There was an MTM gain of INR7.5b related to the remaining stake in GLS (~7%) shown in other income. Further, there was an impairment of (INR40.4b): INR22b related to manufacturing plants, INR11b related to intangibles, INR3.2b related to legal settlements, and INR4.3b related to issues in the Argentina business. Moreover, there was an overall tax outgo of INR17b, leading to a reported loss of INR12b.
- Adjusting for all, PAT surged ~2.5x to INR1.6b (our est: INR1.4b).
- During FY24, revenue grew 2% YoY to INR118b, while EBITDA/PAT declined 20%/81% YoY to INR13b/INR700m.

## Highlights from the management commentary

- GNP guided 14-18% YoY revenue growth to INR135-INR140b, with 19% EBITDA margin for FY25.
- GNP filed for g-Flovent in May'24. One more pMDI to be filed in FY25.
- GNP is also planning to launch WINLEVI in select markets in Europe in FY26.

Quarterly performance											(INRm)	
Y/E March	FY23				FY24				FY23	FY24	Estimate	
	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q				
<b>Net Revenues (Core)</b>	<b>27,773</b>	<b>30,179</b>	<b>31,002</b>	<b>30,005</b>	<b>30,361</b>	<b>32,074</b>	<b>25,067</b>	<b>30,630</b>	<b>1,15,832</b>	<b>1,18,131</b>	<b>32,187</b>	<b>-4.8</b>
YoY Change (%)	-6.3	0.5	3.3	-0.6	9.3	6.3	-19.1	2.1	-4.5	2.0	-4.6	
<b>EBITDA</b>	<b>4,726</b>	<b>5,220</b>	<b>4,740</b>	<b>3,979</b>	<b>4,374</b>	<b>5,053</b>	<b>-1,444</b>	<b>5,043</b>	<b>16,350</b>	<b>13,025</b>	<b>4,297</b>	<b>17.4</b>
YoY Change (%)	-17.6	0.0	-9.2	-20.8	-7.5	-3.2	PTL	26.7	-25.3	-20.3	-29.0	
Margins (%)	17.0	17.3	15.3	13.3	14.4	15.8	-5.8	16.5	14.1	11.0	13.4	
Depreciation	1,468	1,458	1,515	1,350	1,420	1,415	1,471	1,513	5,692	5,819	1,223	
<b>EBIT</b>	<b>3,258</b>	<b>3,762</b>	<b>3,225</b>	<b>2,629</b>	<b>2,953</b>	<b>3,638</b>	<b>-2,915</b>	<b>3,530</b>	<b>10,658</b>	<b>7,206</b>	<b>3,075</b>	
YoY Change (%)	-29.2	-6.7	-20.0	-29.1	-9.4	-3.3	-190.4	34.3	-37.4	-32.4	-32.9	
Margins (%)	11.7	12.5	10.4	8.8	9.7	11.3	-11.6	11.5	9.2	6.1	9.6	
Interest	600	829	971	1,091	1,116	1,215	1,343	1,486	3,490	5,160	1,310	
Other Income	172	864	374	-424	197	17	454	7,732	2,889	8,400	400	
<b>PBT before EO Expense</b>	<b>2,830</b>	<b>3,797</b>	<b>2,629</b>	<b>1,113</b>	<b>2,034</b>	<b>2,441</b>	<b>-3,805</b>	<b>9,776</b>	<b>10,057</b>	<b>10,447</b>	<b>2,165</b>	<b>351.6</b>
One-off loss/(gain)	-1,250	430	-669	7,997	520	3,684	1,409	4,468	7,659	10,082	0	
<b>PBT after EO Expense</b>	<b>4,080</b>	<b>3,367</b>	<b>3,297</b>	<b>-6,884</b>	<b>1,514</b>	<b>-1,244</b>	<b>-5,214</b>	<b>5,308</b>	<b>2,398</b>	<b>364</b>	<b>2,164</b>	<b>145.3</b>
Tax	1,969	1,648	1,441	-1,389	1,137	559	-718	17,695	3,294	18,673	550	
Rate (%)	48.3	49.0	43.7	20.2	75.1	-45.0	13.8	333.3	137.3	5,123.0	25.4	
<b>Reported PAT</b>	<b>2,111</b>	<b>1,719</b>	<b>1,856</b>	<b>-5,495</b>	<b>377</b>	<b>-1,803</b>	<b>-4,496</b>	<b>-12,386</b>	<b>-896</b>	<b>-18,309</b>	<b>1,614</b>	<b>-867.3</b>
Minority Interest	186	182	182	252	232	204	206	40	802	681	200	
<b>Reported PAT after Minority Interest</b>	<b>1,925</b>	<b>1,536</b>	<b>1,675</b>	<b>-5,747</b>	<b>145</b>	<b>-2,007</b>	<b>-4,701</b>	<b>-12,427</b>	<b>-1,697</b>	<b>-18,990</b>	<b>1,415</b>	
<b>Adj PAT</b>	<b>1,682</b>	<b>2,324</b>	<b>1,298</b>	<b>483</b>	<b>1,111</b>	<b>1,397</b>	<b>-3,486</b>	<b>1,680</b>	<b>3,728</b>	<b>701</b>	<b>1,415</b>	<b>18.7</b>
YoY Change (%)	-39.8	2.3	-42.8	-74.9	-34.0	-39.9	PTL	247.6	-61.8	-81.2	-38.6	
Margins (%)	6.1	7.7	4.2	1.6	3.7	4.4	-13.9	5.5	3.2	0.6	4.4	
<b>Adj. PAT from discontinued operations</b>	<b>1,087</b>	<b>1,069</b>	<b>1,050</b>	<b>1,464</b>	<b>1,355</b>	<b>1,187</b>	<b>1,188</b>	<b>244</b>	<b>4,670</b>	<b>3,973</b>	<b>22</b>	<b>984.3</b>
YoY Change (%)												
<b>Overall Adj. PAT</b>	<b>2,769</b>	<b>3,392</b>	<b>2,348</b>	<b>1947</b>	<b>2,465</b>	<b>2,584</b>	<b>(2,299)</b>	<b>1923</b>	<b>8398</b>	<b>4674</b>	<b>1437</b>	<b>33.8</b>

E: MOFSL Estimates Note: Sum of 4 quarter for FY23 will not match as 1QFY24 is not restated

Key performance Indicators												
Y/E March	FY23				FY24				FY23	FY24	FY24	4QE
	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q				
India formulations	10,352	10,916	10,745	8,284	10,643	11,217	2,622	9,391	40,297	29,945	9,771	
YoY Change (%)	-15.5	12.7	6.7	-6.4	2.8	2.8	-75.6	13.4	-1.4	-15.6	18.0	
US	6,628	7,533	8,373	8,507	8,085	7,392	7,629	7,557	31,041	24,413	8,732	
YoY Change (%)	-15.9	-0.1	10.7	15.3	22.0	-1.9	-8.9	-11.2	2.2	-0.3	2.6	
ROW+LatAm	4,226	6,154	6,541	6,856	5,512	7,324	7,250	7,528	23,777	19,551	7,349	
YoY Change (%)	25.7	-17.8	22.3	25.1	30.4	19.0	10.8	9.8	9.7	16.4	7.2	
Europe	3,300	3,785	4,932	6,078	5,732	5,997	6,357	6,118	18,095	14,795	6,884	
YoY Change (%)	7.9	11.9	29.6	22.3	73.7	58.4	28.9	0.7	18.9	33.8	13.3	
<b>Cost Break-up</b>												
RM Cost (% of Sales)	36.4	35.6	34.4	38.5	39.1	37.3	41.2	32.5	36.8	37.4	37.9	
Staff Cost (% of Sales)	22.9	22.7	22.8	20.5	22.4	22.8	30.0	22.9	22.5	24.3	23.0	
R&D Expenses(% of Sales)	10.7	10.9	8.9	11.2	9.3	10.1	12.3	10.0	16.3	10.3	8.7	
Other Cost (% of Sales)	12.9	13.5	18.6	16.6	14.7	13.9	22.2	18.2	10.4	17.0	17.0	
Gross Margin (%)	63.6	64.4	65.6	61.5	60.9	62.7	58.8	67.5	63.2	62.6	62.1	
EBITDA Margin (%)	17.0	17.3	15.3	13.3	14.4	15.8	-5.8	16.5	14.1	11.0	13.4	
EBIT Margin (%)	11.7	12.5	10.4	8.8	9.7	11.3	-11.6	11.5	9.2	6.1	9.6	

E: MOFSL Estimates




## Highlights from the management commentary


- It filed two/four ANDAs in 4QFY24/FY24.
- GNP expects approval of Ryaltris in the Brazilian market in FY26
- The company has completed remediation measures for the Monroe plant. The company expects the site to be inspected by the USFDA in the coming months.
- The innovation R&D expenses would be USD50m for FY25 and would reduce in FY26. The overall R&D spending would be 7.0-7.25% of sales.
- Gross debt was INR9.9b at the end of the quarter
- GNP exhibited 3% YoY growth in the consumer care segment for 4QFY24.
- GNP outperformed IPM in the DF segment by 5.8pp/2.5pp for 4QFY24/FY24.

## Key exhibits (including GLS revenue)


### Exhibit 1: DF sales grew 13.4% YoY in 4QFY24




### Exhibit 2: NA sales declined 11.2% YoY in 4QFY24




### Exhibit 3: Total revenue grew 2.1% YoY in 4QFY24




### Exhibit 4: Gross margin expanded 600bp in 4QFY24



### Exhibit 5: GNP reported 16.5% margin in 4QFY24



### Exhibit 6: Interest coverage ratio at 29.5% in 4QFY24



## Valuation and view

### DF: Re-modeled distribution/in-licensing/new launches to aid growth

- In FY24, GNP's DF sales declined 15.6% YoY to INR34b due to the one-time impact of stock points and rationalization of channel inventories. GNP continued to witness robust traction in certain therapies, such as Cardiac.
- GNP has signed an in-licensing agreement with Pfizer for the launch of Abrocitinib to treat moderate-to-severe atopic dermatitis.
- In FY24, GCC's primary sales grew 14% YoY, driven largely by core brands such as Candid powder (up 15% YoY) and Scalpe (up 23% YoY). Further, the company launched various line extensions of the existing brands, driving growth further.
- We expect a 15% CAGR in DF sales to INR45.2b over FY24-26 led by niche launches/market share gains, and inflation-linked upward revisions in prices.

### US: addressing regulatory issues/niche pipeline remain the key for growth

- In FY24, the US sales stood flat YoY to INR30.9b (CC: down 2.5% to USD374m) due to the lack of new product launches and a delay in the scale-up of recent launches.
- GNP filed six ANDAs in FY24 and received three approvals in the US market. Further, it has launched several products under licensing agreements, including Varenicline Tablets, Fosphenytoin Sodium Injection USP, and Ketorolac Tromethamine Injection in the US market.
- It has filed three respiratory products, including g-Flovent in the US market. Further, it plans to file at least one more respiratory pMDI product in that market in FY25.
- GNP has completed the remediation process at its Monroe plant and anticipates inspection in the near term.
- We expect the US sales to clock a 5% CAGR to reach USD416m over FY24-26.

### EU: Market share gains/expansion in new geographies driving growth

- In FY24, GNP's EU sales jumped 33.8% YoY to INR24.2b, driven by steady expansion in the generics market and strong growth in the branded market.
- The overall growth was due to Slovakia, and Poland, which registered double-digit growth in addition to the strong uptake in the respiratory therapy.
- Across the CEE markets, key brands such as Ryaltris and Salmex/Asthmex continue to sustain their market share, both in terms of volume as well as value.
- GNP is waiting for approvals of four respiratory brands and is planning to launch Winlevi in select markets in the EU in FY26.
- Consequently, we expect 14% sales CAGR to INR31.5b over FY24-26.

### RoW – Robust performance across regions


- In FY24, RoW sales grew 16.4% to INR27.7b. This growth was due to derma/respiratory launches driving strong growth in the base business across all the sub-regions of the ROW market.
- Further, Ryaltris is a leading nasal spray in markets like South Africa. Additionally, Ryaltris is doing well in the Asia market. It expects to launch Ryaltris in the UAE market in the coming quarters.
- In LATAM, respiratory is the key contributor to growth, with Glenmark achieving its highest market share in the respiratory category in Mexico.

- Over FY24-26, we expect a 9% sales CAGR to INR32.7b on the back of market share gains in respiratory/derma and new launches across these regions.

### Maintain Neutral

- We raise our earnings estimates by 17%/10% for FY25/FY26, factoring in: 1) new launches in the US market, 2) increased market share in cardiac, derma, and respiratory products in the Domestic Formulation (DF) segment, and c) a significant reduction in interest costs. **We value GNP at 21x 12M forward earnings to arrive at our TP of INR1,050.**
- GNP ended FY24 with an adj. PAT of INR700m, the lowest historically. However, new approvals in the US, changes in distribution model in the DF business, and financial deleverage would enable a sharp revival in earnings over FY24-26. The current valuation adequately captures the improvement in earnings over the next two years. **Reiterate Neutral.**

**Exhibit 7: P/E chart**




**Exhibit 8: EV/EBITDA chart**




## Story in charts

Exhibit 9: Expect sales CAGR of 10.5% over FY24–26




Source: Company, MOFSL

Exhibit 10: EBITDA margin to expand 750bp over FY24–26




Source: Company, MOFSL

Exhibit 11: R&amp;D spending as a percentage of sales to be stable over FY24–26




Source: Company, MOFSL

Exhibit 12: Low base to drive strong EPS growth over FY24–26



Source: Company, MOFSL

Exhibit 13: ROE to improve over FY24–26



Source: Company, MOFSL

Note: Above Charts excludes GLS consolidation

## Financials and valuations

Income Statement								(INRm)
Y/E March	FY19	FY20	FY21	FY22	FY23	FY24	FY25E	FY26E
<b>Net Sales</b>	<b>97,051</b>	<b>1,03,972</b>	<b>1,09,439</b>	<b>1,21,339</b>	<b>1,15,832</b>	<b>1,18,131</b>	<b>1,32,536</b>	<b>1,44,242</b>
Change (%)	8.2	7.1	5.3	10.9	-4.5	2.0	12.2	8.8
<b>EBITDA</b>	<b>14,504</b>	<b>14,793</b>	<b>21,544</b>	<b>21,881</b>	<b>16,350</b>	<b>13,025</b>	<b>24,189</b>	<b>26,753</b>
Change (%)	-2.3	2.0	45.6	1.6	-25.3	-20.3	85.7	10.6
Margin (%)	14.9	14.2	19.7	18.0	14.1	11.0	18.3	18.5
Depreciation	3,259	4,172	4,436	4,867	5,692	5,819	5,035	5,191
<b>EBIT</b>	<b>11,245</b>	<b>10,622</b>	<b>17,108</b>	<b>17,014</b>	<b>10,658</b>	<b>7,206</b>	<b>19,155</b>	<b>21,563</b>
Interest	3,346	3,773	3,531	2,981	3,490	5,160	666	396
OI & forex gains/losses	2,105	2,623	501	617	2,889	8,400	350	390
<b>PBT before EO Expense</b>	<b>10,004</b>	<b>9,472</b>	<b>14,078</b>	<b>14,650</b>	<b>10,057</b>	<b>10,447</b>	<b>18,838</b>	<b>21,556</b>
Change (%)	-10.6	-5.3	48.6	4.1	-31.3	3.9	80.3	14.4
Extra Ordinary Expense	-3,002	-1,489	255	237	7,659	10,082	0	0
<b>PBT after EO Exp.</b>	<b>13,006</b>	<b>10,961</b>	<b>13,824</b>	<b>14,412</b>	<b>2,398</b>	<b>364</b>	<b>18,838</b>	<b>21,556</b>
Tax	3,756	3,201	4,124	4,476	3,294	18,673	6,405	7,329
Tax Rate (%)	28.9	29.2	29.8	31.1	137.3	5123.0	34.0	34.0
<b>Reported PAT</b>	<b>9,250</b>	<b>7,760</b>	<b>9,700</b>	<b>9,417</b>	<b>-1,697</b>	<b>-18,990</b>	<b>12,433</b>	<b>14,227</b>
Minority Interest	0	0	0	519	802	681	0	0
<b>Adj PAT from continuing ops.</b>	<b>7,312</b>	<b>6,938</b>	<b>9,871</b>	<b>9,752</b>	<b>5,836</b>	<b>701</b>	<b>12,433</b>	<b>14,227</b>
Change (%)	-9.0	-5.1	42.3	-1.2	-40.2	-88.0	NA	14.4
Margin (%)	7.5	6.7	9.0	8.0	5.0	0.6	9.4	9.9
<b>Adj. PAT from discontinuing ops</b>					<b>4,670</b>	<b>3,973</b>		
<b>Overall PAT</b>	<b>7,312</b>	<b>6,938</b>	<b>9,871</b>	<b>9,752</b>	<b>10,506</b>	<b>4,674</b>	<b>12,433</b>	<b>14,227</b>
Change (%)	-9.0	-5.1	42.3	-1.2	7.7	-55.5	166.0	14.4

Balance Sheet								(INRm)
Y/E March	FY19	FY20	FY21	FY22	FY23	FY24	FY25E	FY26E
Equity Share Capital	282	282	282	282	282	282	282	282
Reserves	55,770	60,423	70,364	90,584	94,457	78,197	89,610	1,03,837
<b>Net Worth</b>	<b>56,052</b>	<b>60,705</b>	<b>70,646</b>	<b>90,866</b>	<b>94,739</b>	<b>78,479</b>	<b>89,893</b>	<b>1,04,119</b>
Minority Interest	-4	-4	-4	3,515	3,653	-4	-4	-4
Loans	38,768	44,856	44,018	36,703	43,477	9,906	9,906	9,906
Deferred liabilities	-13830	-14393	-15059	-16546	-18054	-10494	-10493	-10492
<b>Capital Employed</b>	<b>80,986</b>	<b>91,164</b>	<b>99,602</b>	<b>1,14,538</b>	<b>1,23,816</b>	<b>77,887</b>	<b>89,301</b>	<b>1,03,529</b>
Gross Block	59,080	76,501	82,266	93,966	94,115	87,819	93,819	99,819
Less: Accum. Deprn.	20,732	24,903	29,339	34,206	39,898	45,717	50,751	55,942
<b>Net Fixed Assets</b>	<b>38,348</b>	<b>51,598</b>	<b>52,927</b>	<b>59,760</b>	<b>54,217</b>	<b>42,102</b>	<b>43,067</b>	<b>43,876</b>
Capital WIP	12,344	10,906	12,178	9,211	11,896	6,619	6,619	6,619
Investments	297	246	246	496	446	7,897	7,897	7,897
Intangibles (net)	17,370	21,821	23,349	22,854	22,925	10,920	10,920	10,920
<b>Curr. Assets</b>	<b>68,070</b>	<b>69,541</b>	<b>75,338</b>	<b>84,504</b>	<b>1,03,507</b>	<b>76,472</b>	<b>76,579</b>	<b>90,128</b>
Inventory	22,521	21,356	22,768	24,998	23,736	25,131	26,507	28,848
Account Receivables	21,946	24,090	25,721	31,011	36,652	18,584	27,597	30,429
Cash and Bank Balance	9,378	11,112	11,392	14,115	11,603	16,595	6,769	13,757
Others	14,226	12,982	15,457	14,379	31,516	16,163	15,706	17,094
<b>Curr. Liability &amp; Prov.</b>	<b>38,072</b>	<b>41,127</b>	<b>41,087</b>	<b>39,433</b>	<b>46,251</b>	<b>55,202</b>	<b>44,860</b>	<b>44,991</b>
Account Payables	33,689	35,975	35,944	34,519	41,331	48,791	41,758	41,889
Provisions	4,384	5,152	5,143	4,914	4,920	6,411	3,102	3,102
<b>Net Current Assets</b>	<b>29,998</b>	<b>28,414</b>	<b>34,250</b>	<b>45,071</b>	<b>57,256</b>	<b>21,270</b>	<b>31,719</b>	<b>45,137</b>
<b>Appl. of Funds</b>	<b>80,986</b>	<b>91,164</b>	<b>99,602</b>	<b>1,14,538</b>	<b>1,23,816</b>	<b>77,887</b>	<b>89,301</b>	<b>1,03,529</b>

E: MOFSL Estimates

## Financials and valuations

Ratios								
Y/E March	FY19	FY20	FY21	FY22	FY23	FY24	FY25E	FY26E
<b>Basic (INR)</b>								
EPS (Fully diluted)*	25.9	24.6	35.0	34.6	20.7	2.5	44.1	50.4
Cash EPS	37.5	39.4	50.7	51.8	40.9	23.1	61.9	68.8
BV/Share	198.6	215.1	250.4	322.0	335.8	278.1	318.6	369.0
DPS	3.0	3.0	3.0	3.0	3.0	3.0	3.0	3.0
Payout (%)	11.0	9.0	7.3	10.8	60.0	-5.4	8.2	0.0
<b>Valuation (x)</b>								
P/E (Fully diluted)	43.4	45.7	32.1	32.5	54.3	452.4	25.5	22.3
Cash P/E	30.0	28.5	22.2	21.7	27.5	48.6	18.2	16.3
P/BV	5.7	5.2	4.5	3.5	3.3	4.0	3.5	3.0
EV/Sales	3.6	3.4	3.2	2.8	3.0	2.6	2.4	2.2
EV/EBITDA	23.9	23.7	16.2	15.5	21.4	23.8	13.2	11.7
Dividend Yield (%)	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.3
<b>Return Ratios (%)</b>								
RoE	13.6	11.9	15.0	12.1	6.3	0.8	14.8	14.7
RoCE	11.6	10.9	13.0	11.4	-4.2	-777.3	15.4	15.0
RoIC	17.3	15.3	17.8	15.3	2.2	-512.6	17.3	15.1
<b>Working Capital Ratios</b>								
Fixed Asset Turnover (x)	2.8	2.3	2.1	2.2	2.0	2.5	3.1	3.3
Debtor (Days)	83	85	86	93	115	57	76	77
Inventory (Days)	85	75	76	75	75	78	73	73
Working Capital (Days)	78	61	76	93	144	14	69	79
<b>Leverage Ratio (x)</b>								
Current Ratio	1.8	1.7	1.8	2.1	2.2	1.4	1.7	2.0
Net Debt/Equity	0.5	0.6	0.5	0.2	0.3	-0.1	0.0	0.0

Cash Flow Statement <span style="float: right;">(INRm)</span>								
Y/E March	FY19	FY20	FY21	FY22	FY23	FY24	FY25E	
Op. Profit/(Loss) before Tax	14,504	14,793	21,544	21,881	16,350	13,025	24,189	26,753
Interest/Dividends Recd.	2,105	2,623	501	617	2,889	8,400	350	390
Direct Taxes Paid	-4,383	-3,764	-4,791	-5,963	-4,802	-11,114	-6,404	-7,328
(Inc)/Dec in WC	8,169	3,318	-5,557	-8,097	-14,698	40,978	-20,275	-6,429
<b>CF from Operations</b>	<b>20,395</b>	<b>16,971</b>	<b>11,697</b>	<b>8,438</b>	<b>-260</b>	<b>51,290</b>	<b>-2,140</b>	<b>13,386</b>
EO Expense	-3,002	-1,489	255	237	7,659	10,082	0	0
<b>CF frm Op.incl EO Exp.</b>	<b>13,242</b>	<b>13,242</b>	<b>13,242</b>	<b>8,201</b>	<b>-7,919</b>	<b>41,208</b>	<b>-2,140</b>	<b>13,386</b>
(Inc)/Dec in FA	-12,437	-15,984	-7,036	-8,733	-2,834	11,574	-6,000	-6,000
<b>Free Cash Flow</b>	<b>805</b>	<b>-2,742</b>	<b>6,205</b>	<b>-533</b>	<b>-10,753</b>	<b>52,781</b>	<b>-8,140</b>	<b>7,386</b>
(Pur)/Sale of Investments	-150	51	0	-250	50	-7,450	0	0
<b>CF from Investments</b>	<b>-6,990</b>	<b>-6,990</b>	<b>-6,990</b>	<b>-8,983</b>	<b>-2,784</b>	<b>4,123</b>	<b>-6,000</b>	<b>-6,000</b>
Change in Networth	-3,814	-2,409	952	11,822	6,589	3,749	-1	-1
Inc/(Dec) in Debt	-5,601	6,088	-837	-3,797	6,912	-37,228	0	0
Interest Paid	-3,346	-3,773	-3,531	-2,981	-3,490	-5,160	-666	-396
Dividend Paid	-1,019	-698	-710	-1,019	-1,019	-1,019	-1,019	0
<b>CF from Fin. Activity</b>	<b>-7,387</b>	<b>-7,387</b>	<b>-7,387</b>	<b>3,516</b>	<b>8,992</b>	<b>-39,658</b>	<b>-1,686</b>	<b>-397</b>
<b>Inc/Dec of Cash</b>	<b>-1,136</b>	<b>-1,136</b>	<b>-1,136</b>	<b>2,733</b>	<b>-1,711</b>	<b>5,673</b>	<b>-9,826</b>	<b>6,988</b>
Add: Beginning Balance	12,347	9,378	11,112	11,392	14,115	11,603	16,595	6,769
Effect of exchange rate	-1,833	2,871	1,415	0	-802	-681	0	0
<b>Closing Balance</b>	<b>9,378</b>	<b>11,113</b>	<b>11,392</b>	<b>14,115</b>	<b>11,603</b>	<b>16,595</b>	<b>6,769</b>	<b>13,757</b>

E: MOFSL Estimates

Investment in securities market are subject to market risks. Read all the related documents carefully before investing

Explanation of Investment Rating	
Investment Rating	Expected return (over 12-month)
BUY	>=15%
SELL	< - 10%
NEUTRAL	< - 10 % to 15%
UNDER REVIEW	Rating may undergo a change
NOT RATED	We have forward looking estimates for the stock but we refrain from assigning recommendation

\*In case the recommendation given by the Research Analyst is inconsistent with the investment rating legend for a continuous period of 30 days, the Research Analyst shall be within following 30 days take appropriate measures to make the recommendation consistent with the investment rating legend.

#### Disclosures

The following Disclosures are being made in compliance with the SEBI Research Analyst Regulations 2014 (herein after referred to as the Regulations).

Motilal Oswal Financial Services Ltd. (MOFSL) is a SEBI Registered Research Analyst having registration no. INH000000412. MOFSL, the Research Entity (RE) as defined in the Regulations, is engaged in the business of providing Stock broking services, Depository participant services & distribution of various financial products. MOFSL is a listed public company, the details in respect of which are available on [www.motilaloswal.com](http://www.motilaloswal.com). MOFSL (erstwhile Motilal Oswal Securities Limited - MOSL) is registered with the Securities & Exchange Board of India (SEBI) and is a registered Trading Member with National Stock Exchange of India Ltd. (NSE) and Bombay Stock Exchange Limited (BSE), Multi Commodity Exchange of India Limited (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) for its stock broking activities & is Depository participant with Central Depository Services Limited (CDSL) National Securities Depository Limited (NSDL), NERL, COMRIS and CCR and is member of Association of Mutual Funds of India (AMFI) for distribution of financial products and Insurance Regulatory & Development Authority of India (IRDA) as Corporate Agent for insurance products. Details of associate entities of Motilal Oswal Financial Services Limited are available on the website at <http://onlinereports.motilaloswal.com/Dormant/documents/ListOf%20of%20Associate%20companies.pdf>

MOFSL and its associate company(ies), their directors and Research Analyst and their relatives may; (a) from time to time, have a long or short position in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein; (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.

MOFSL and / or its affiliates do and seek to do business including investment banking with companies covered in its research reports. As a result, the recipients of this report should be aware that MOFSL may have a potential conflict of interest that may affect the objectivity of this report. Compensation of Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions. Details of pending Enquiry Proceedings of Motilal Oswal Financial Services Limited are available on the website at <https://galaxy.motilaloswal.com/ResearchAnalyst/PublishViewLitigation.aspx>

A graph of daily closing prices of securities is available at [www.nseindia.com](http://www.nseindia.com), [www.bseindia.com](http://www.bseindia.com). Research Analyst views on Subject Company may vary based on Fundamental research and Technical Research. Proprietary trading desk of MOFSL or its associates maintains arm's length distance with Research Team as all the activities are segregated from MOFSL research activity and therefore it can have an independent view with regards to Subject Company for which Research Team have expressed their views.

#### Regional Disclosures (outside India)

This report is not directed or intended for distribution to or use by any person or entity resident in a state, country or any jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL & its group companies to registration or licensing requirements within such jurisdictions.

#### For Hong Kong:

This report is distributed in Hong Kong by Motilal Oswal capital Markets (Hong Kong) Private Limited, a licensed corporation (CE AYY-301) licensed and regulated by the Hong Kong Securities and Futures Commission (SFC) pursuant to the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) "SFO". As per SEBI (Research Analyst Regulations) 2014 Motilal Oswal Securities (SEBI Reg. No. INH000000412) has an agreement with Motilal Oswal capital Markets (Hong Kong) Private Limited for distribution of research report in Hong Kong. This report is intended for distribution only to "Professional Investors" as defined in Part I of Schedule 1 to SFO. Any investment or investment activity to which this document relates is only available to professional investor and will be engaged only with professional investors." Nothing here is an offer or solicitation of these securities, products and services in any jurisdiction where their offer or sale is not qualified or exempt from registration. The Indian Analyst(s) who compile this report is/are not located in Hong Kong & are not conducting Research Analysis in Hong Kong.

#### For U.S.

Motilal Oswal Financial Services Limited (MOFSL) is not a registered broker - dealer under the U.S. Securities Exchange Act of 1934, as amended (the "1934 act") and under applicable state laws in the United States. In addition MOFSL is not a registered investment adviser under the U.S. Investment Advisers Act of 1940, as amended (the "Advisers Act" and together with the 1934 Act, the "Acts"), and under applicable state laws in the United States. Accordingly, in the absence of specific exemption under the Acts, any brokerage and investment services provided by MOFSL, including the products and services described herein are not available to or intended for U.S. persons. This report is intended for distribution only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the Exchange Act and interpretations thereof by SEC (henceforth referred to as "major institutional investors"). This document must not be acted on or relied on by persons who are not major institutional investors. Any investment or investment activity to which this document relates is only available to major institutional investors and will be engaged in only with major institutional investors. In reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act") and interpretations thereof by the U.S. Securities and Exchange Commission ("SEC") in order to conduct business with Institutional Investors based in the U.S., MOFSL has entered into a chaperoning agreement with a U.S. registered broker-dealer, Motilal Oswal Securities International Private Limited. ("MOSIPL"). Any business interaction pursuant to this report will have to be executed within the provisions of this chaperoning agreement.

The Research Analysts contributing to the report may not be registered /qualified as research analyst with FINRA. Such research analyst may not be associated persons of the U.S. registered broker-dealer, MOSIPL, and therefore, may not be subject to NASD rule 2711 and NYSE Rule 472 restrictions on communication with a subject company, public appearances and trading securities held by a research analyst account.

#### For Singapore

In Singapore, this report is being distributed by Motilal Oswal Capital Markets (Singapore) Pte. Ltd. ("MOCMSPL") (UEN 201129401Z), which is a holder of a capital markets services license and an exempt financial adviser in Singapore. This report is distributed solely to persons who (a) qualify as "institutional investors" as defined in section 4A(1)(c) of the Securities and Futures Act of Singapore ("SFA") or (b) are considered "accredited investors" as defined in section 2(1) of the Financial Advisers Regulations of Singapore read with section 4A(1)(a) of the SFA. Accordingly, if a recipient is neither an "institutional investor" nor an "accredited investor", they must immediately discontinue any use of this Report and inform MOCMSPL.

In respect of any matter arising from or in connection with the research you could contact the following representatives of MOCMSPL. In case of grievances for any of the services rendered by MOCMSPL write to [grievances@motilaloswal.com](mailto:grievances@motilaloswal.com).

Nainesh Rajani

Email: [nainesh.rajani@motilaloswal.com](mailto:nainesh.rajani@motilaloswal.com)

Contact: (+65) 8328 0276

#### Specific Disclosures

- 1 MOFSL, Research Analyst and/or his relatives does not have financial interest in the subject company, as they do not have equity holdings in the subject company.
- 2 MOFSL, Research Analyst and/or his relatives do not have actual/beneficial ownership of 1% or more securities in the subject company
- 3 MOFSL, Research Analyst and/or his relatives have not received compensation/other benefits from the subject company in the past 12 months
- 4 MOFSL, Research Analyst and/or his relatives do not have material conflict of interest in the subject company at the time of publication of research report
- 5 Research Analyst has not served as director/officer/employee in the subject company
- 6 MOFSL has not acted as a manager or co-manager of public offering of securities of the subject company in past 12 months
- 7 MOFSL has not received compensation for investment banking/ merchant banking/brokerage services from the subject company in the past 12 months
- 8 MOFSL has not received compensation for other than investment banking/merchant banking/brokerage services from the subject company in the past 12 months
- 9 MOFSL has not received any compensation or other benefits from third party in connection with the research report
- 10 MOFSL has not engaged in market making activity for the subject company

The associates of MOFSL may have:

- financial interest in the subject company
- actual/beneficial ownership of 1% or more securities in the subject company at the end of the month immediately preceding the date of publication of the Research Report or date of the public appearance.
- received compensation/other benefits from the subject company in the past 12 months
- any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.
- acted as a manager or co-manager of public offering of securities of the subject company in past 12 months

- be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies)
- received compensation from the subject company in the past 12 months for investment banking / merchant banking / brokerage services or from other than said services.
- Served subject company as its clients during twelve months preceding the date of distribution of the research report.

The associates of MOFSL has not received any compensation or other benefits from third party in connection with the research report

Above disclosures include beneficial holdings lying in demat account of MOFSL which are opened for proprietary investments only. While calculating beneficial holdings, It does not consider demat accounts which are opened in name of MOFSL for other purposes (i.e holding client securities, collaterals, error trades etc.). MOFSL also earns DP income from clients which are not considered in above disclosures.

#### Analyst Certification

The views expressed in this research report accurately reflect the personal views of the analyst(s) about the subject securities or issues, and no part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations and views expressed by research analyst(s) in this report.

#### Terms & Conditions:

This report has been prepared by MOFSL and is meant for sole use by the recipient and not for circulation. The report and information contained herein is strictly confidential and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of MOFSL. The report is based on the facts, figures and information that are considered true, correct, reliable and accurate. The intent of this report is not recommendatory in nature. The information is obtained from publicly available media or other sources believed to be reliable. Such information has not been independently verified and no warranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. The report is prepared solely for informational purpose and does not constitute an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments for the clients. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. MOFSL will not treat recipients as customers by virtue of their receiving this report.

#### Disclaimer:

The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent. This report and information herein is solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult its own advisors to determine the merits and risks of such an investment. The investment discussed or views expressed may not be suitable for all investors. Certain transactions -including those involving futures, options, another derivative products as well as non-investment grade securities - involve substantial risk and are not suitable for all investors. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information and opinions contained in this document. The Disclosures of Interest Statement incorporated in this document is provided solely to enhance the transparency and should not be treated as endorsement of the views expressed in the report. This information is subject to change without any prior notice. The Company reserves the right to make modifications and alterations to this statement as may be required from time to time without any prior approval. MOFSL, its associates, their directors and the employees may from time to time, effect or have effected an own account transaction in, or deal as principal or agent in or for the securities mentioned in this document. They may perform or seek to perform investment banking or other services for, or solicit investment banking or other business from, any company referred to in this report. Each of these entities functions as a separate, distinct and independent of each other. The recipient should take this into account before interpreting the document. This report has been prepared on the basis of information that is already available in publicly accessible media or developed through analysis of MOFSL. The views expressed are those of the analyst, and the Company may or may not subscribe to all the views expressed therein. This document is being supplied to you solely for your information and may not be reproduced, redistributed or passed on, directly or indirectly, to any other person or published, copied, in whole or in part, for any purpose. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction. Neither the Firm, not its directors, employees, agents or representatives shall be liable for any damages whether direct or indirect, incidental, special or consequential including lost revenue or lost profits that may arise from or in connection with the use of the information. The person accessing this information specifically agrees to exempt MOFSL or any of its affiliates or employees from, any and all responsibility/liability arising from such misuse and agrees not to hold MOFSL or any of its affiliates or employees responsible for any such misuse and further agrees to hold MOFSL or any of its affiliates or employees free and harmless from all losses, costs, damages, expenses that may be suffered by the person accessing this information due to any errors and delays.

This report is meant for the clients of Motilal Oswal only.

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Registered Office Address: Motilal Oswal Tower, Rahimtullah Sayani Road, Opposite Parel ST Depot, Prabhadevi, Mumbai-400025; Tel No.: 022 - 71934200 / 71934263; [www.motilaloswal.com](http://www.motilaloswal.com).

Correspondence Address: Palm Spring Centre, 2nd Floor, Palm Court Complex, New Link Road, Malad (West), Mumbai- 400 064. Tel No: 022 71881000. Details of Compliance Officer: Neeraj Agarwal, Email Id: [na@motilaloswal.com](mailto:na@motilaloswal.com), Contact No.:022-40548085.

Grievance Redressal Cell:

Contact Person	Contact No.	Email ID
Ms. Hemangi Date	022 40548000 / 022 67490600	<a href="mailto:query@motilaloswal.com">query@motilaloswal.com</a>
Ms. Kumud Upadhyay	022 40548082	<a href="mailto:servicehead@motilaloswal.com">servicehead@motilaloswal.com</a>
Mr. Ajay Menon	022 40548083	<a href="mailto:jam@motilaloswal.com">jam@motilaloswal.com</a>

Registration details of group entities.: Motilal Oswal Financial Services Ltd. (MOFSL): INZ000158836 (BSE/NSE/MCX/NCDEX); CDSL and NSDL: IN-DP-16-2015; Research Analyst: INH000000412 . AMFI: ARN : 146822. IRDA Corporate Agent – CA0579. Motilal Oswal Financial Services Ltd. is a distributor of Mutual Funds, PMS, Fixed Deposit, Insurance, Bond, NCDs and IPO products.

Customer having any query/feedback/ clarification may write to [query@motilaloswal.com](mailto:query@motilaloswal.com). In case of grievances for any of the services rendered by Motilal Oswal Financial Services Limited (MOFSL) write to [grievances@motilaloswal.com](mailto:grievances@motilaloswal.com), for DP to [dpgrievances@motilaloswal.com](mailto:dpgrievances@motilaloswal.com).